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Abstract :  
DNA gyrase and topoisomerase IV are type IIa topoisomerases that are essential bacterial 
enzymes required to oversee the topological state of DNA during transcription and replication 
processes. Their ATPase domains, GyrB and ParE, respectively, are recognized as viable 
targets for small molecule inhibitors, however, no synthetic or natural product GyrB/ParE 
inhibitors have so far reached the clinic for use as novel antibacterial agents, except for 
novobiocin which was withdrawn from the market. In the present study, a series of substituted 
oxadiazoles have been designed and synthesized as potential DNA gyrase inhibitors. 
Structure-based optimization resulted in the identification of compound 35, displaying an IC50 
of 1.2 µM for Escherichia coli DNA gyrase, while also exhibiting a balanced low micromolar 
inhibition of E. coli topoisomerase IV and of the respective Staphylococcus aureus 
homologues. The most promising inhibitors identified from each series were ultimately 
evaluated against selected Gram-positive and Gram-negative bacterial strains, of which 
compound 35 inhibited Enterococcus faecalis with a MIC90 of 75 µM. Our study thus 
provides further insight into the structural requirements of substituted oxadiazoles for dual 
inhibition of DNA gyrase and topoisomerase IV. 
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The incidence of infections resistant to all currently used antibacterial drugs has increased 
dramatically in the past decade [1]. The emerging resistance extends to both Gram-positive 
and Gram-negative organisms and constitutes a serious threat to successful antibacterial 
therapy [2]. One approach to tackling this issue successfully is to develop novel agents that 
inhibit known and novel bacterial targets via unique binding sites or via novel modes of action 
[3]. 
 
DNA gyrase and topoisomerase IV are bacterial type IIa topoisomerases and pivotal enzymes 
required in overseeing the topological state of DNA during transcription and replication 
processes [4]. While DNA gyrase is essential for the initiation of DNA replication, elongation 
of nascent DNA and the negative supercoiling of DNA during replication, topoisomerase IV 
is involved primarily in DNA decatenation at the end of replication [5]. The inhibition of one 
or both of these enzymes results in the disruption of DNA synthesis, in turn leading to cell 
death. DNA gyrase and topoisomerase IV are heterotetramers, formed by association of 
subunits GyrA and GyrB or ParC and ParE, respectively [6-8]. DNA gyrase and 
topoisomerase IV are clinically validated targets, their druggability being well established in 
two classes of antibiotics - the fluoroquinolones and aminocoumarins. The fluoroquinolones 
interact with the GyrA and ParC domain, while aminocoumarins target the GyrB and ParE 
domains [9]. Of note, DNA gyrase and topoisomerase IV enzymes act in an ATP-dependent 
manner, relying on their ATPase domains, GyrB and ParE, respectively, for providing the 
energy required for the extensive conformational changes [6]. Their ATP binding pockets 
exhibit high homology among bacteria, but at the same time low homology with eukaryotes 
[4]. They have been recognized early on as potential targets for small molecule inhibitors 
[7,10,11], however, to date, no synthetic or natural product GyrB/ParE inhibitors since 
 
 
novobiocin which was withdrawn from the market have reached the clinic due to different 
issues such as resistance, toxicity and permeability [12]. The GyrB/ParE ATP-binding 
subunits, therefore, are still insufficiently exploited targets for the development of novel 
antibacterial agents [13]. 
 
Novobiocin and clorobiocin belong to a class of structurally closely related naturally 
occurring antibiotics, the aminocoumarins (see Fig. 1). Clorobiocin features a pyrrole moiety 
replacing the carbamate group of novobiocin and a chlorine atom instead of a methyl group. 
The most essential interaction between these aminocoumarins and the ATP-binding site is 
achieved in E. coli via Asp73 residue and the associated water molecule [7]. Cyclothialidines 
(see Fig. 1) constitute the second class of naturally occuring DNA gyrase ATPase inhibitors 
[14-16]. These provide proof of tolerance of the ATP binding site of DNA gyrase to 
significant chemical diversity [7]. The X-ray crystal structures of coumarins and 
cyclothialidines bound to the ATP-binding pocket of DNA gyrase further have reinforced that 
conclusion, revealing that the carbamate of novobiocin, the 2-carboxypyrrole of clorobiocin, 
and the phenol group of cyclothialidine, are all able to interact with the Asp73 residue and its 
hydrogen-bonded conserved water molecule [6]. 
 
Figure 1. Naturally occurring DNA gyrase inhibitors  
 
The crystal structure of DNA gyrase B was first solved by Wigley in 1991, laying the 
groundwork for further research in this field [17]. The X-ray structure information on the 
binding modes of cyclothialidine and novobiocin to the ATP binding site of GyrB [18,19] as 
 
 
well as the ligand-based inhibitor design [15,16] had established a broad knowledge of the 
structure-activity relationships (SAR), providing a strong basis for the rational design of novel 
inhibitors and at the same time enabling further optimization of lead structures.  
 
Figure 2. Representative examples of synthetic DNA gyrase and/or topoisomerase IV inhibitors. 
 
The binding modes of the reported inhibitors revealed an overlapping site of interaction, 
namely a set of hydrogen bonds provided by Asp73 and an associated conserved water 
molecule. This interaction is essential, and almost indispensable. Nevertheless, other unique 
structural and electronic characteristics of the binding-site pocket have also been taken into 
account in the design process. The common structural features of synthesized inhibitors also 
include functionalities making use of interactions with (i) Arg136; (ii) an additional 
hydrophobic pocket composed of Val71, Val43, Val167, and Ala147; (iii) a hydrophobic floor 
consisting of Pro79, Ile78 and Ile94 and (iv) and a π-stacking ceiling formed by Arg76 in a 
Glu50-Arg76 salt bridge. The ligand-based and fragment-based approaches as well as the 
targeted screening programs have identified numerous GyrB inhibitors with diverse scaffolds, 
such as novobiocin and cyclothialidine analogs [15,16,20], arylaminotriazines [21], 
 
 
arylaminopyrimidines [2], indazoles [22], pyrazolopyridones [23], pyrrolopyrimidines 
[11,13], pyridylureas [24], pyrrolamides [25] and tricyclic pyrimidinoindoles [26], thus 
providing several additional starting points for medicinal chemists (structures are shown in 
Fig. 2). 
 
Currently, there is a pressing need for new antibacterial compounds [27]. Compound XIV 
(Fig. 3), a low nanomolar GyrB inhibitor based on a thiazole-piperidine central core has 
recently been disclosed as part of a series of promising pyrrolamide GyrB inhibitors [9]. Its 
development, however, was discontinued mostly due to unfavorable pharmacokinetics. 
Therefore, we explored possible replacements of the thiazole-piperidine core of XIV to find 
another scaffold that could provide different SAR and optimization opportunities. 
Oxadiazoles are considered important constituents of biologically active compounds, 
exhibiting a wide range of effects, which makes them attractive building blocks for a variety 
of purposes [28-30]. The main objective of the present study was to identify small molecule 
inhibitors of DNA gyrase based on a novel phenyl-substituted oxadiazole central scaffold by 
utilising their structural similarity to the known pyrrolamide XIV.  
 
2. RESULTS AND DISCUSSION 
2.1 Design 
Our design was based on the structures of the recently disclosed series of pyrrolamide GyrB 
inhibitors carrying a thiazole-piperidine central core and represented by compound XIV [9]. 
Making use of both ligand-based as well as structure-based approaches, we chose this 
inhibitor as lead and designed a small library of its analogs based on a substituted 5-phenyl-
1,2,4-oxadiazole central scaffold (Fig. 3). The thiazole-carboxylic acid moiety was 
bioisosterically replaced by an oxadiazole-carboxylic acid. The aromatic nature of this 
 
 
heterocycle is key for optimizing π-stacking with Arg76 and hydrogen bond interactions with 
Arg136, while the pendant carboxylic acid function provides an additional interaction with 
Arg136. The Glu50-Arg76 salt bridge has also been taken into account, as it is prone to a π-
cation interaction with the oxadiazole moiety of the inhibitors. 
 
Figure 3. Design of oxadiazole-based DNA gyrase inhibitors. 
 
The pyrrole NH group of XIV has been shown to interact with the Asp73-water H-bond motif 
in the GyrB ATP-binding pocket, indicating a certain degree of similarity of this series to 
clorobiocin and kibdelomycin [31]. Of note, some of the reported ATP-competitive DNA 
gyrase inhibitors (e.g. clorobiocin) feature substituted pyrrole moieties in their structures. It 
has been demonstrated that, by attaching small lipophilic groups to the pyrrole ring, stronger 
interactions with the left-hand side lipophilic pocket of GyrB can be achieved. Similarly, 
several DNA gyrase inhibitors possessing pyrrole, dibromopyrrole and bromopyrrole moieties 
in their structures have been identified [32-36]. Thus, the 5-methyl-3,4-dichloropyrrole 
moiety of the parent compound was replaced by various heterocyclic moieties, such as indole, 
pyrrole, 4-bromopyrrole, 4,5-dibromopyrrole and 5-fluoroindole moieties to probe the 
chemical space of the left-hand side lipophilic pocket. The selection of compounds for the 
synthesis was guided and corroborated by molecular docking of candidate molecules into the 
 
 
DNA gyrase ATP-binding site (PDB code: 4DUH). Analysis of the results of molecular 
docking of compound 19 in the ATP-binding site of E. coli DNA gyrase revealed possible 
hydrophobic interactions of the indole moiety in the hydrophobic pocket formed by Val43, 
Val71, Val120 and Val167.  
 
a b  
Figure 4. The binding mode of inhibitors a) 19 (in green sticks) and b) 34 (in yellow sticks) in the ATP-
binding site of E. coli DNA gyrase B (PDB code: 4DUH) as predicted by docking with LeadIT [37]. The ligand 
and neighboring protein side chains are colored according to the chemical atom type (C19 in green, C34 in yellow, 
CGyrB in gray, N in blue, O in red, and Br in brown). Hydrogen bonds are indicated by black dotted lines. Figure 
was prepared by PyMOL [38]. 
 
Moreover, 19 was also predicted to form two hydrogen bonds – one with Asp73 side chain 
and the other with the conserved water molecule bridged to Asp73 carboxylate. In addition, 
the oxadiazole nucleus is predicted to form cation-π interaction with Arg76 side chain, further 
reinforcing the binding, while it also forms a hydrogen bond with Arg136 side chain (Fig. 4a). 
The terminal carboxylate bound to the oxadiazole ring was predicted to form two additional 
hydrogen bonds with Arg136, thus additionally constraining the inhibitor in the binding site 
(Fig. 4a). 
 
Synthesis of the second series of compounds was also guided by molecular docking of 
candidate molecules into the DNA gyrase ATP-binding site. These compounds feature a 
methylene/imine linker connecting the phenyl and 1,2,4-oxadiazole moieties, inserted in the 
 
 
central scaffold. By inserting a flexible linker, we attempted to direct the carboxylic acid 
functionality toward the Arg136 in the binding site, as predicted by molecular docking of 
compound 34 (Fig. 4b). In this case, the imine hydrogen was predicted to form an additional 
hydrogen bond with Gly101, as seen in the case of GyrB inhibitors discovered by Brvar et al 
[39]. The indole, 4,5-dibromopyrrole and 5-methyl-3,4-dichloropyrrole moieties, which 
proved to be the most appropriate to fit the left-hand side hydrophobic pocket of DNA gyrase, 
have been retained in the structures of this novel series of inhibitors (Fig. 3).  
 
2.2 Chemistry  
The starting esters 1-5 were obtained by coupling the corresponding carboxylic acids with 
ethyl m-aminobenzoate using the standard TBTU methodology. The subsequent alkaline 
hydrolysis of esters 1-5 yielded the acylated derivatives of m-aminobenzoic acid 6-10. The 
latter were coupled with ethyl 2-oximinooxamate (Scheme 1) using TBTU-coupling 
conditions (adapted from [40]). The afforded O-acyl amidoximes were immediately subjected 
to cyclization conditions using KF in 1,4-dioxane at 110 °C, thereby giving the corresponding 
ethyl 1,2,4-oxadiazole-3-carboxylates 11-15. Final deprotection of ethyl esters was achieved 
by alkaline hydrolysis using 1M NaOH/THF mixture [41], affording the final compounds, the 
1,2,4-oxadiazole-3-carboxylic acids 16 (pyrrole derivative), 17 (4-bromopyrrole derivative), 
18 (4,5-dibromopyrrole derivative), 19 (indole derivative) and 20 (5-fluoroindole derivative). 
A different path was chosen for the synthesis of the 1,3,4-oxadiazole-incorporating congeners 
(outlined in Scheme 1). The key intermediate amine 21, synthesized as described [42], was N-
deprotected under acidolytic conditions and then coupled with indole-2-carboxylic acid using 
TBTU-coupling conditions to afford the corresponding amide 22. Deprotection of ethyl 1,3,4-
oxadiazole-2-carboxylate 22 was achieved by alkaline hydrolysis using 1M NaOH/THF 
mixture, but the compound underwent a decarboxylation and instead of affording the desired 
 
 
1,3,4-oxadiazole-2-carboxylic acid, the decarboxylated derivative 23 was formed. Compound 
22 was further derivatized into a more stable amide derivative 24. Aminolysis of ethyl ester 
22 was achieved by bubbling ammonia gas through its ethanolic solution at 0 °C, thereby 
achieving complete conversion to the amide derivative 24. 
 
 
Scheme 1. Synthesis of oxadiazole-based DNA gyrase inhibitors. Reagents and conditions: (i) 
1M NaOH/THF; (ii) a) ethyl 2-oximinooxamate, TBTU, DIPEA, DMAP, CH2Cl2 b) KF, 1,4-
dioxane, 110 °C; (iii) TFA/CH2Cl2 (1:5); (iv) indole-2-carboxylic acid, TBTU, DIPEA, 
DMAP, CH2Cl2, reflux; (v) NH3 (g)/EtOH, 0 °C. 
 
Compound 14 was further derivatized to its corresponding amide derivative 25 as well as its 
hydroxamic acid derivative 26 (Scheme 2). Aminolysis of ethyl ester 14 was achieved by 
bubbling ammonia gas through an ethanolic solution of the compound at 0 °C. Hydroxamic 
acid 26 was synthesized by a different route [40]. Compound 14 was dissolved in methanol; a 
methanolic solution of hydroxylamine was then added, followed by the addition of a catalytic 
 
 
amount of KCN. The reaction mixture was stirred at room temperature until the starting 
compound was completely converted to the hydroxamic acid derivative 26.  
 
Scheme 2. Synthesis of carboxamide and hydroxamic acid derivatives of 14. Reagents and 
conditions: (i) NH3 (g)/EtOH, 0 °C; (ii) NH2OH×HCl, KOH, KCN, MeOH. 
 
Synthesis of the second-generation oxadiazole-based DNA gyrase inhibitors is presented in 
Scheme 3. The key intermediate ethyl 1,2,4-oxadiazole-3-carboxylate 27 was synthesized as 
described previously [42]. Subsequently, N-Boc protecting group was removed under 
acidolytic conditions, giving the free amine intermediate which was then coupled with 
different acids (indole-2-carboxylic acid and 4,5-dibromopyrrole-2-carboxylic acid) using 
TBTU-coupling conditions to afford the corresponding amides 28 and 29. Deprotection of 
esters was achieved by alkaline hydrolysis using 1M NaOH/THF mixture, affording the end 
compounds 1,2,4-oxadiazole-3-carboxylic acids 30 (indole derivative) and 31 (4,5-
dibromopyrrole derivative). Compounds 34 and 35 were synthesized by a different route 
(Scheme 3). First, ethyl 2-oximinooxamate was reacted with trichloroacetic acid anhydride 
(TCAA) at 140 °C for 3 h, yielding the 5-trichloromethyl-1,2,4-oxadiazole intermediate [43]. 
In the following step, the 5-trichloromethyl derivative 32 underwent a nucleophilic 
displacement with p-phenylenediamine in the presence of DMAP in refluxing chloroform to 
afford compound 33 (adapted by [44]). The latter was then coupled with 4,5-dibromopyrrole-
2-carboxylic acid or 3,4-dichloro-5-methylpyrrole-2-carboxylic acid using TBTU-coupling 
 
 
conditions to afford the corresponding amides which were immediately used in the next step, 




Scheme 3. Synthesis of second-generation oxadiazole based DNA gyrase inhibitors. Reagents 
and conditions: (i) TFA/CH2Cl2 (1:5); (ii) indole-2-carboxylic acid or 4,5-diBr-pyrrole-2-
carboxylic acid, TBTU, DIPEA, DMAP, CH2Cl2, reflux; (iii) 1M NaOH/THF; (iv) 
trichloroacetic acid anhydride, 140 °C; (v) p-phenylenediamine, DMAP, chloroform, reflux; 
(vi) 4,5-diBr-pyrrole-2-carboxylic acid or 3,4-diCl-5-methylpyrrole-2-carboxylic acid, TBTU, 
DIPEA, DMAP, CH2Cl2. 
 
2.3 Biological data 
2.3.1 In vitro enzyme inhibition 
Initial screening of the first series of compounds in the E. coli DNA gyrase supercoiling assay 
comprising GyrA and GyrB subunits of DNA gyrase (Table 1) highlighted the importance of 
the indole moiety for DNA gyrase inhibition in concert with the free carboxylic acid 
functionality located on the 1,2,4-oxadiazole nucleus, as seen in the case of the best inhibitor 




Table 1. Inhibitory activities of oxadiazole-based inhibitors 
 
aResidual activity of the enzyme at 100 µM of the tested compound. 
b1% DMSO was used as a negative control. 
cnovobiocin was used as a positive control. 
dn.d. – not determined. 
 
    
compound R       X Y 
DNA gyrase 
RA [%]a, b  or IC50 [μM] 
topoisomerase IV 
RA [%]a, b  or IC50 
[μM] 
E. coli S. aureus E. coli S. aureus 
novobiocinc - - - 0.17  μM 0.040  μM 11  μM 27  μM 
11 pyrrole-2-yl COOEt - 86% nd nd nd 
12 4-Br-pyrrole-2-yl COOEt - 71 % nd nd nd 
13 4,5-diBr-pyrrole-2-yl COOEt - 98 % nd nd nd 
14 indole-2-yl COOEt - 97% nd nd nd 
15 5-F-indole-2-yl COOEt - 148% 
 
nd nd nd 
16 pyrrole-2-yl COOH - 92% 
 
nd nd nd 
17 4-Br-pyrrole-2-yl COOH - 61% 
 
nd nd nd 
18 4,5-diBr-pyrrole-2-yl COOH - 61 μM nd nd nd 
19 indole-2-yl COOH - 4.0  μM 88% 100% 88% 
20 5-F-indole-2-yl COOH - 144 % 
 
nd nd nd 
22 - COOEt - 133 % 
 
nd nd nd 
23 - H - 106% nd nd nd 
24 - CONH2 - 81 % nd nd nd 
25 indole-2-yl CONH2 - 91 % nd nd nd 
26 indole-2-yl CONHOH - 92 % nd nd nd 
30 indole-2-yl - CH2 82% nd nd nd 
31 4,5-diBr-pyrrole-2-yl - CH2 66 µM nd nd nd 
34 4,5-diBr-pyrrole-2-yl - NH 5.8 µM nd nd nd 
35 3,4-diCl-5-methylpyrrole-2-yl - NH 1.2 µM 12 μM 135 μM 15 μM 
 
 
The importance of hydrophobic interactions of the inhibitors was further supported by the 
inactivity of the pyrrole analogue 16 and weak activity of the 4-bromopyrrole-based 
compound 17 [IC50 > 100 µM]. Their 4,5-dibromopyrrole congener 18 [IC50 = 61 µM] 
possessed 15-fold weaker inhibitory activity than compound 19. Hydrophobic pocket of the 
ATP-binding site of E. coli GyrB was further probed by the 5-fluoroindole-based 20, however 
the resulting compound displayed a complete lack of activity, indicating that the 5-
fluoroindole moiety is most likely too large to fit into this pocket. The ethyl esters 11 
(pyrrole-based), 12 (4-bromopyrrole-based), 13 (4,5-dibromopyrrole-based), 14 (indole-
based) and 15 (5-fluoroindole-based) were completely devoid of inhibitory activity. Based on 
the results of this preliminary screening, compound 19 was selected for further exploration of 
its chemical space. Interestingly, its carboxamide analog 25 and its hydroxamic acid analog 
26 were completely devoid of any inhibitory activity. Synthesis of the regioisomer of 1,2,4-
oxadiazole 19, incorporating the 1,3,4-oxadiazole moiety, was also attempted via alkaline 
hydrolysis of the corresponding ethyl ester analog 22. The free 1,3,4-oxadiazole-3-carboxylic 
acid however proved unstable and underwent an immediate decarboxylation, affording the 
des-carboxy derivative 23. The obtained des-carboxy derivative 23 and ester 22 were devoid 
of any inhibitory activity. The carboxamide regioisomer of 25, compound 24, was also 
prepared and also showed no inhibitory activity. 
 
Screening of the second-generation of compounds (see Table 1) highlighted the importance of 
the 4,5-dibromopyrrole moiety and the free carboxylic acid functionality for DNA gyrase 
inhibition. Interestingly, as opposed to the results of the first generation of compounds, the 
indole-based and methylene linker-containing free acid 30 was completely devoid of 
inhibitory activity, while its 4,5-dibromopyrrole-incorporating counterpart 31 [IC50 = 66 µM] 
was moderately inhibitory active. The best inhibitors of the second-generation of compounds 
 
 
were compounds carrying the imine linker, namely compounds 34 [IC50 = 5.8 µM] and 35 
[IC50 = 1.2 µM]. Comparing 34 to its methylene linker analog 31, it becomes evident that the 
ability to form an additional hydrogen bond with Gly101 (as shown in Fig. 4b) is reflected in 
a 10-fold lower IC50 value. On the other hand, the new 3,4-dichloro-5-methylpyrrole moiety 
featured in compound 35 further increased hydrophobic interactions in the adenine pocket, 
resulting in slightly stronger inhibitory activity than 34. Moreover, the flexible imine linker 
orients the carboxylic acid moieties of 34 and 35 to face the Arg136 side chain, forming two 
hydrogen bonds and resulting in stronger inhibitory activities of these two inhibitors than 19 
and 18. The best compounds of each series, compounds 19 and 35, were additionally tested 
for their potential inhibition of E. coli topoisomerase IV and of Staphylococcus aureus DNA 
gyrase and topoisomerase IV homologs. Compound 19 was inactive, while the 3,4-dichloro-5-
methylpyrrole-based oxadiazole inhibitor 35 showed promising inhibitory activity against all 
four tested enzymes in the micromolar range (IC50 values from 1.2 to 135 µM). The inhibitory 
potencies of 35 against DNA gyrase [IC50 (E. coli) = 1.2 µM] and topoisomerase IV [IC50 (E. 
coli) = 135 µM] from E. coli were approximately 10-fold lower than those of novobiocin. 
Nevertheless, for the S. aureus enzymes, the IC50 values were more comparable. In fact, 
inhibition of topoisomerase IV by 35 [IC50 (S. aureus) = 15 µM] was even better than that of 
novobiocin [IC50 (S. aureus) = 27 µM], while the reverse was the case for DNA gyrase [35: 
IC50 (S. aureus) = 12 µM; novobiocin: (IC50 (S. aureus) = 0.040 µM)]. 
 
2.3.2 Antibacterial activity 
Oxadiazoles 18, 19 and 35 were tested against two Gram-positive (Staphylococcus aureus 
ATCC 25923, Enterococcus faecalis ATCC 29212) and two Gram-negative (Escherichia coli 
ATCC 25922, Pseudomonas aeruginosa ATCC 27853) bacterial strains. In general, the 
compounds exhibited no significant antibacterial activities against Gram-positive bacteria and 
 
 
only a weak growth inhibition of S. aureus (inhibitions ≤38% at 50 µM concentration; data 
not shown). The only notable activity was observed against E. faecalis for compound 35 
which showed >80% inhibition of the growth of E. faecalis in the primary screen at 50 µM 
and the MIC90 determined by dose-response experiments was 75 µM. None of the compounds 
showed any antibacterial activity against the tested Gram-negative bacteria. Further 
optimization of physicochemical properties of compounds and their enzyme inhibitory 




In conclusion, two series of substituted oxadiazoles have been prepared originating from the 
structure XIV. Iterative cycles of structure-based optimization resulted in compound 35 which 
displayed an IC50 of 1.2 µM of E.coli DNA gyrase and proved to be the most potent of the 
series. The docking experiments suggest that this class of inhibitors bind to the ATP-binding 
site of the enzyme. It is noteworthy, that compound 35 also exhibited a balanced micromolar 
inhibition of E. coli topoisomerase IV and of the Staphylococcus aureus homologs. 
Furthermore, it also exhibited a modest inhibition against Enterococcus faecalis (MIC90 = 75 
µM). Overall, the results offer a valuable insight into the structural requirements of 
substituted oxadiazoles for DNA gyrase inhibition and thus provide a good foundation for 
further research in this field. 
 
4. EXPERIMENTAL SECTION 
4.1 Materials and methods 
Chemicals were obtained from Acros, Sigma-Aldrich and TCI, and used without further 
purification. Analytical TLC was performed on Merck 60 F254 silica gel plates (0.25 mm), 
 
 
using visualization with ultraviolet light and ninhydrin. Column chromatography was carried 
out on silica gel 60 (particle size 240-400 mesh). Melting points were determined on a 
Reichert hot stage microscope and are uncorrected. 1H- and 13C-NMR spectra were recorded 
at 400 MHz and 100 MHz, respectively, on a Bruker AVANCE III spectrometer in DMSO-d6, 
MeOD or CDCl3 solution with TMS as the internal standard. Spectra were assigned using 
gradient HSQC and HMBC techniques. IR spectra were recorded on a Perkin-Elmer 1600 FT-
IR spectrometer. Mass spectra were obtained using a VG-Analytical Autospec Q mass 
spectrometer. Microanalyses were performed on a 240 C Perkin-Elmer CHN analyzer. HPLC 
analyses were performed on an Agilent Technologies HP 1100 instrument with G1365B UV-
VIS detector (254 nm), using a Luna C18 column (4.6 × 150 mm) at a flow rate of 1 mL/min. 
The eluent was a mixture of 0.1% TFA in water (A) and acetonitrile (B), with a gradient of 
30% B to 80% B from 0-30 minutes and 80% B to 90% B from 30-33 minutes. 
 
4.2 General procedures 
4.2.1 Formation of 1,2,4-oxadiazoles 
To a stirred solution of carboxylic acid derivative (1.0 eq) in dried tetrahydrofuran (THF), 
diisopropylethylamine (3.0 eq) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
tetrafluoroborate (TBTU) (1.1 eq) were added. After stirring for 45 minutes ethyl 2-
oximinooxamate (1.0 eq) and a catalytic amount of 4-dimethylaminopyridine (DMAP) (0.1 
eq) were added and the mixture stirred at room temperature for an additional 2 h. The solvent 
was then removed in vacuo to afford the crude product. This was used without purification in 
the next step in which it was dissolved in dry 1,4-dioxane (5 mL).  Potassium fluoride (3.0 eq) 
was then added and the mixture was heated at 80 °C for 24 h. On completion, the reaction 
mixture was concentrated in vacuo and the residue purified by flash silica gel column 
 
 
chromatography (gradient elution; starting eluent: hexane/ethyl acetate 3:1 v/v) to afford the 
desired compounds 11-15. 
 
4.2.2 Acidolytic cleavage of Boc protecting groups and the subsequent TBTU-mediated 
coupling 
To an ice-chilled stirred mixture of trifluoroacetic acid (TFA) and dichloromethane (v/v 1/5, 5 
mL) Boc-protected compound (1.0 eq) was added and the mixture allowed to warm to room 
temperature. After 3 h the reaction was complete and the solvent was evaporated in vacuo. 
The residue was washed three times with diethyl ether giving a crude ammonium salt which 
was dissolved in dichloromethane followed by the addition of diisopropylethylamine (1.0 eq). 
In a parallel reaction, to a stirred solution of indole-2-carboxylic acid or 4,5-dibromo-pyrrole-
2-carboxylic acid (1.0 eq) in dry dichloromethane (10 mL), diisopropylethylamine (3.0 eq) 
and TBTU (1.1 eq) were added. After stirring for 45 minutes the solution of free amine in 
dichloromethane was added at 0 °C, and the mixture was allowed to warm to room 
temperature. Stirring was continued for 48 h. On completion, the reaction mixture was diluted 
with dichloromethane (30 mL) then washed with 1M HCl (2 × 20 mL), water (20 mL), 
saturated NaHCO3 solution (2 × 20 mL), water (20 mL) and dried over anhydrous Na2SO4. 
The solvent was concentrated in vacuo and the residue purified by flash silica gel column 
chromatography (gradient elution; starting eluent: hexane/ethyl acetate 2:1 v/v) to afford the 
corresponding amides 22, 28 and 29. 
 
4.2.3 TBTU-mediated coupling 
To a stirred solution of carboxylic acid (1.0 eq) in dry dichloromethane (10 mL), 
diisopropylethylamine (3.0 eq) and TBTU (1.1 eq) were added. After stirring for 45 minutes 
ethyl m-aminobenzoate was added at 0 °C, and the mixture allowed to warm to room 
 
 
temperature; stirring then continued for 48 h. On completion, the reaction mixture was diluted 
with dichloromethane (30 mL) then washed with 1M HCl (2 × 20 mL), water (20 mL), 
saturated NaHCO3 solution (2 × 20 mL), water (20 mL) and dried over anhydrous Na2SO4. 
The solvent was concentrated in vacuo to afford the desired amides 1-5. 
 
4.2.4 Alkaline hydrolysis 
To a solution of the corresponding ester (1 eq) in THF, 1M NaOH (5 eq) was added and the 
reaction mixture stirred at room temperature for 5 h. THF was evaporated under vacuum and 
the resulting aqueous solution neutralized with 1M HCl until the product started to precipitate. 
The product was filtered off, then dried to afford the desired acids 6-10. 
 
4.3 Characterization of compounds 
4.3.1 Ethyl 3-(1H-pyrrole-2-carboxamido)benzoate (1). Synthesized according to the general 
procedure for TBTU-mediated coupling. Beige amorphous powder; m.p. 158-160 °C. 1H-
NMR (DMSO-d6, 400 MHz): δ = 1.34 (t, 3H, J = 7.2 Hz, -CH2-CH3), 4.34 (q, 2H, J = 7.2 Hz, 
-CH2-CH3), 6.18-6.20 (m, 1H, Ar-H), 6.99-7.00 (m, 1H, Ar-H), 7.11-7.13 (m, 1H, Ar-H), 7.48 
(t, 1H, J = 8.0 Hz, Ar-H), 7.64-7.66 (m, 1H, Ar-H), 8.07-8.10 (m, 1H, Ar-H), 8.38 (t, 1H, J = 
2.0 Hz, Ar-H), 9.98 (s, 1H, -CONH), 11.71 (s, 1H, pyrrole-NH) ppm. MS (ESI): m/z (%) = 
259.1 (M+H)+. IR (KBr): n = 3330, 2982, 1760, 1714, 1628, 1594, 1549, 1529, 1439, 1403, 
1366, 1333, 1317, 1283, 1264, 1233, 1159, 1130, 1096, 1047, 1023, 1000, 946, 904, 741, 682, 
671, 603 cm-1. HRMS Calcd for C14H15N2O3 m/z: 259.1083 (M+H)+, found 259.1077.  
 
4.3.2 Ethyl 3-(4-bromo-1H-pyrrole-2-carboxamido)benzoate (2). Synthesized according to 
the general procedure for TBTU-mediated coupling. Beige amorphous powder; m.p. 208-211 
°C. 1H-NMR (DMSO-d6, 400 MHz): δ = 1.34 (t, 3H, J = 7.2 Hz, -CH2-CH3), 4.34 (q, 2H, J = 
 
 
7.2 Hz, -CH2-CH3), 7.13-7.15 (m, 1H, Ar-H), 7.21-7.22 (m, 1H, Ar-H), 7.50 (t, 1H, J = 8.0 
Hz, Ar-H), 7.67 (dd, 1H, J = 8.0 Hz, J = 1,2 Hz, Ar-H), 8.05-8.08 (m, 1H, Ar-H), 8.37 (t, 1H, 
J = 2.0 Hz, Ar-H), 10.04 (s, 1H, -CONH), 12.11 (s, 1H, pyrrole-NH) ppm. 13C-NMR (DMSO-
d6, 100 MHz): δ = 14.16, 60.78, 95.28, 112.97, 120.25, 122.67, 123.79, 124.16, 126.33, 
129.10, 130.31, 139.39, 158.18, 165.59 ppm. MS (ESI): m/z (%) = 337.0 (M+H)+. IR (KBr): 
n = 3387, 3352, 3224, 3123, 2976, 1695, 1652, 1597, 1556, 1534, 1431, 1384, 1365, 1332, 
1294, 1263, 1235, 1184, 1141, 1090, 920, 755 cm-1. HRMS Calcd for C14H14BrN2O3 m/z: 
337.0188 (M+H)+, found 337.0197. 
 
4.3.3 Ethyl 3-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzoate (3). Synthesized according 
to the general procedure for TBTU-mediated coupling. Beige amorphous powder; m.p. 235-
237 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 1.34 (t, 3H, J = 7.2 Hz, -CH2-CH3), 4.34 (q, 2H, 
J = 7.2 Hz, -CH2-CH3), 7.28 (d, 1H, J = 2.4 Hz, Ar-H), 7.50 (t, 1H, J = 8.0 Hz, Ar-H), 7.66-
7.69 (m, 1H, Ar-H), 8.04-8.07 (m, 1H, Ar-H), 8.35 (t, 1H, J = 2.0 Hz, Ar-H), 10.08 (s, 1H, -
CONH), 12.97 (s, 1H, pyrrole-NH) ppm. 13C-NMR (DMSO-d6, 100 MHz): δ = 14.16, 60.80, 
98.24, 106.23, 114.08, 120.27, 123.93, 124.17, 127.62, 129.16, 130.34, 139.22, 157.43, 
165.56 ppm. MS (ESI): m/z (%) = 414.9 (M+H)+. IR (KBr): n = 3341, 3175, 3128, 1686, 
1651, 1588, 1552, 1523, 1439, 1394, 1287, 1274, 1231, 1183, 752 cm-1. HRMS Calcd for 
C14H13Br2N2O3 m/z: 414.9293 (M+H)+, found 414.9302.  
 
4.3.4 Ethyl 3-(1H-indole-2-carboxamido)benzoate (4). Synthesized according to the general 
procedure for TBTU-mediated coupling. Beige amorphous powder; m.p. 214-217 °C. 1H-
NMR (DMSO-d6, 400 MHz): δ = 1.36 (t, 3H, J = 7.2 Hz, -CH2-CH3), 4.35 (q, 2H, J = 7.2 Hz, 
-CH2-CH3), 7.09 (t, 1H, J = 8.0 Hz, Ar-H), 7.24 (t, 1H, J = 8.0 Hz, Ar-H), 7.47-7.49 (m, 2H, 
Ar-H), 7.54 (t, 1H, J = 8.0 Hz, Ar-H), 7.69-7.72 (m, 2H, Ar-H), 8.14-8.17 (m, 1H, Ar-H), 
 
 
8.46 (t, 1H, J = 2.0 Hz, Ar-H), 10.45 (s, 1H, -CONH), 11.79 (s, 1H, indole-NH) ppm. MS 
(ESI): m/z (%) = 309.1 (M+H)+. IR (KBr): n = 3350, 3303, 1686, 1655, 1588, 1536, 1439, 
1420, 1395, 1369, 1317, 1290, 1236, 1196, 1168, 1144, 1106, 743, 681 cm-1. HRMS Calcd 
for C18H17N2O3 m/z: 309.1239 (M+H)+, found 309.1233. 
 
4.3.5 Ethyl 3-(5-fluoro-1H-indole-2-carboxamido)benzoate (5). Synthesized according to the 
general procedure for TBTU-mediated coupling. Beige amorphous powder; m.p. 183-186 °C. 
1H-NMR (DMSO-d6, 400 MHz): δ = 1.34 (t, 3H, J = 7.2 Hz, -CH2-CH3), 4.34 (q, 2H, J = 7.2 
Hz, -CH2-CH3), 7.10 (dt, 1H, J = 9.2 Hz, J = 2.4 Hz, Ar-H), 7.45-7.55 (m, 4H, Ar-H), 7.70 
(td, 1H, J = 8.0 Hz, J = 1.2 Hz, Ar-H), 8.14-8.16 (m, 1H, Ar-H), 8.45 (t, 1H, J = 2.0 Hz, Ar-
H), 10.51 (s, 1H, -CONH), 11.92 (s, 1H, indole-NH) ppm. MS (ESI): m/z (%) = 325.1 (M-H)-
. IR (KBr): n = 3347, 3297, 1685, 1655, 1590, 1537, 1439, 1423, 1369, 1283, 1236, 1206, 
1146, 1105, 856, 798, 751, 733, 682 cm-1. HRMS Calcd for C18H15FN2O3 m/z: 325.0988 (M-
H)-, found 325.0990.  
 
4.3.6 3-(1H-pyrrole-2-carboxamido)benzoic acid (6). Synthesized according to the general 
procedure for alkaline hydrolysis described. Beige amorphous powder; m.p. 234-236 °C. 1H-
NMR (DMSO-d6, 400 MHz): δ = 6.18 (s, 1H, Ar-H), 6.98 (s, 1H, Ar-H), 7.11 (s, 1H, Ar-H), 
7.45 (t, 1H, J = 8.0 Hz, Ar-H), 7.63 (d, 1H, J = 7.6 Hz, Ar-H), 8.06 (d, 1H, J = 8.0 Hz, Ar-H), 
8.34 (s, 1H, Ar-H), 9.93 (s, 1H, -CONH), 11.67 (s, 1H, pyrrole-NH), 12.92 (s, 1H, COOH) 
ppm. MS (ESI): m/z (%) = 229.1 (M-H)-. IR (KBr): n = 3336, 2819, 2563, 1689, 1626, 1592, 
1551, 1529, 1448, 1395, 1296, 1272, 1167, 1157, 1132, 750 cm-1. HRMS Calcd for 




4.3.7 3-(4-Bromo-1H-pyrrole-2-carboxamido)benzoic acid (7). Synthesized according to the 
general procedure for alkaline hydrolysis. Beige amorphous powder; m.p. 264-266 °C. 1H-
NMR (DMSO-d6, 400 MHz): δ = 7.12 (s, 1H, Ar-H), 7.20 (s, 1H, Ar-H), 7.46 (t, 1H, J = 8.0 
Hz, Ar-H), 7.65 (d, 1H, J = 7.6 Hz, Ar-H), 8.03 (d, 1H, J = 8.0 Hz, Ar-H), 8.33 (s, 1H, Ar-H), 
10.00 (s, 1H, -CONH), 12.07 (s, 1H, pyrrole-NH), 12.97 (s, 1H, COOH) ppm. MS (ESI): m/z 
(%) = 307.0 (M-H)-. IR (KBr): n = 3523, 3396, 3284, 2981, 1735, 1695, 1652, 1574, 1540, 
1478, 1445, 1419, 1379, 1314, 1274, 1240, 1213, 741, 670 cm-1. HRMS Calcd for 
C12H8BrN2O3 m/z: 306.9718 (M-H)-, found 306.9719. 
 
4.3.8 3-(4,5-Dibromo-1H-pyrrole-2-carboxamido)benzoic acid (8). Synthesized according to 
the general procedure for alkaline hydrolysis. Beige amorphous powder; m.p. 265-268 °C. 1H-
NMR (DMSO-d6, 400 MHz): δ = 7.26 (s, 1H, Ar-H), 7.44 (t, 1H, J = 8.0 Hz, Ar-H), 7.65 (d, 
1H, J = 7.6 Hz, Ar-H), 8.02 (d, 1H, J = 8.4 Hz, Ar-H), 8.3o (s, 1H, Ar-H), 10.02 (s, 1H, -
CONH), 12.93 (br s, 2H, COOH, pyrrole-NH) ppm. MS (ESI): m/z (%) = 384.9 (M-H)-. IR 
(KBr): n = 3197, 2864, 1696, 1669, 1550, 1522, 1487, 1436, 1387, 1229, 1178 cm-1. HRMS 
Calcd for C12H7Br2N2O3 m/z: 384.8823 (M-H)-, found 384.8819. 
  
4.3.9 3-(1H-indole-2-carboxamido)benzoic acid (9). Synthesized according to the general 
procedure for alkaline hydrolysis. Beige amorphous powder; m.p. 268-270 °C. 1H-NMR 
(DMSO-d6, 400 MHz): δ = 7.08 (t, 1H, J = 7.6 Hz, Ar-H), 7.24 (t, 1H, J = 7.6 Hz, Ar-H), 
7.48-7.52 (m, 3H, Ar-H), 7.69 (d, 1H, J = 8.0 Hz, Ar-H), 8.13 (d, 1H, J = 8.4 Hz, Ar-H), 8.43 
(s, 1H, Ar-H), 10.42 (s, 1H, -CONH), 11.78 (s, 1H, indole-NH), 12.99 (s, 1H, COOH) ppm. 
MS (ESI): m/z (%) = 279.1 (M-H)-. IR (KBr): n = 3349, 3009, 2846, 1693, 1638, 1590, 1537, 
1486, 1437, 1411, 1340, 1305, 1271, 1231, 1191, 807, 741, 676, 666 cm-1. HRMS Calcd for 
C16H11N2O3 m/z: 279.0770 (M-H)-, found 279.0775. 
 
 
4.3.10 3-(5-Fluoro-1H-indole-2-carboxamido)benzoic acid (10). Synthesized according to the 
general procedure for alkaline hydrolysis. Beige amorphous powder; m.p. 237-240 °C. 1H-
NMR (DMSO-d6, 400 MHz): δ = 7.09 (dt, 1H, J = 9.2 Hz, J = 2.4 Hz, Ar-H), 7.45-7.50 (m, 
4H, Ar-H), 7.69 (td, 1H, J = 7.6 Hz, J = 1.2 Hz , Ar-H), 8.12-8.15 (m, 1H, Ar-H), 8.46 (t, 1H, 
J = 1.6 Hz, Ar-H), 10.67 (s, 1H, -CONH), 12.06 (s, 1H, indole-NH) ppm. MS (ESI): m/z (%) 
= 297.1 (M-H)-. IR (KBr): n = 3352, 1694, 1643, 1592, 1542, 1446, 1419, 1330, 1311, 1273, 
1252, 1230, 1205, 752, 729, 667 cm-1. HRMS Calcd for C16H10FN2O3 m/z: 297.0675 (M-H)-, 
found 297.0679.  
 
4.3.11 Ethyl 5-(3-(1H-pyrrole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylate (11). 
Synthesized according to the general procedure for acidolytic cleavage of Boc protecting 
groups and the subsequent TBTU-mediated coupling. Beige amorphous powder; m.p. 236-
238 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 1.36 (t, 3H, J = 7.2 Hz, -CH2-CH3), 4.45 (q, 2H, 
J = 7.2 Hz, -CH2-CH3), 6.19-6.20 (m, 1H, Ar-H), 7.01-7.02 (m, 1H, Ar-H), 7.13-7.14 (m, 1H, 
Ar-H), 7.62 (t, 1H, J = 8.0 Hz, Ar-H), 7.83 (dd, 1H, J = 8.4 Hz, J = 1.6 Hz, Ar-H), 8.17 (dd, 
1H, J = 8.0 Hz, J = 2.0 Hz, Ar-H), 8.64 (s, 1H, Ar-H), 10.08 (s, 1H, -CONH), 11.74 (s, 1H, 
pyrrole-NH) ppm. 13C-NMR (DMSO-d6, 100 MHz): δ = 13.88, 62.58, 84.80, 109.10, 111.82, 
118.61, 122.12, 123.04, 123.15, 124.32, 125.56, 130.15, 140.54, 157.18, 159.34, 162.12 ppm. 
MS (ESI): m/z (%) = 325.1 (M-H)-. IR (KBr): n = 3335, 1751, 1628, 1567, 1546, 1525, 1487, 
1475, 1463, 1444, 1430, 1405, 1276, 1197, 1169, 1130, 1094, 749, 739 cm-1. HRMS Calcd 




carboxylate (12). Synthesized according to the general procedure for acidolytic cleavage of 
 
 
Boc protecting groups and the subsequent TBTU-mediated coupling. Beige amorphous 
powder; m.p. 254-256 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 1.36 (t, 3H, J = 7.2 Hz, -CH2-
CH3), 4.45 (q, 2H, J = 7.2 Hz, -CH2-CH3), 7.15-7.16 (m, 1H, Ar-H), 7.22-7.23 (m, 1H, Ar-H), 
7.63 (t, 1H, J = 8.0 Hz, Ar-H), 7.84-7.86 (m, 1H, Ar-H), 8.14-8.16 (m, 1H, Ar-H), 8.62 (t, 1H, 
J = 2.0 Hz, Ar-H), 10.15 (s, 1H, -CONH), 12.14 (s, 1H, pyrrole-NH) ppm. 13C-NMR (DMSO-
d6, 100 MHz): δ = 13.88, 62.59, 83.66, 95.36, 113.17, 118.67, 122.47, 122.95, 124.34, 130.26, 
140.19, 144.20, 158.29, 162.12, 163.29, 176.45 ppm. MS (ESI): m/z (%) = 403.0 (M-H)-. IR 
(KBr): n = 3395, 3241, 3135, 2922, 1726, 1658, 1600, 1559, 1529, 1490, 1431, 1404, 1377, 
1353, 1330, 1292, 1261, 1223, 1169, 1138, 1097, 1078, 1024, 919, 891, 874, 826, 800, 792, 
760, 740, 680, 602 cm-1. HRMS Calcd for C16H12BrN4O4 m/z: 403.0042 (M-H)-, found 
403.0049. HPLC: tr = 18.76 min (97.3% at 254 nm). 
 
4.3.13 Ethyl 5-(3-(4,5-dibromo-1H-pyrrole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-
carboxylate (13). Synthesized according to the general procedure for acidolytic cleavage of 
Boc protecting groups and the subsequent TBTU-mediated coupling. Beige amorphous 
powder; m.p. 265-267 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 1.37 (t, 3H, J = 7.2 Hz, -CH2-
CH3), 4.46 (q, 2H, J = 7.2 Hz, -CH2-CH3), 7.30 (s, 1H, Ar-H), 7.65 (t, 1H, J = 8.0 Hz, Ar-H), 
7.87 (dd, 1H, J = 8.4 Hz, J = 1.6 Hz, Ar-H), 8.14 (dd, 1H, J = 8.4 Hz, J = 1.2 Hz, Ar-H), 8.61 
(d, 1H, J = 2.0 Hz, Ar-H), 10.18 (s, 1H, -CONH), 13.02 (s, 1H, pyrrole-NH) ppm. 13C-NMR 
(DMSO-d6, 100 MHz): δ = 13.87, 62.59, 106.60, 114.25, 118.69, 118.89, 122.59, 123.13, 
124.36, 127.49, 130.30, 140.01, 157.16, 157.54, 162.12, 176.41 ppm. MS (ESI): m/z (%) = 
482.9 (M+H)+. IR (KBr): n = 3398, 3284, 3195, 1731, 1695, 1664, 1593, 1525, 1488, 1437, 
1413, 1376, 1350, 1327, 1297, 1272, 1220, 1113, 1078, 741, 676 cm-1. HRMS Calcd for 




4.3.14 Ethyl 5-(3-(1H-indole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylate (14). 
Synthesized according to the general procedure for acidolytic cleavage of Boc protecting 
groups and the subsequent TBTU-mediated coupling. Yellow amorphous powder; m.p. 179-
182 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 1.37 (t, 3H, J = 7.2 Hz, -CH2-CH3), 4.46 (q, 2H, 
J = 7.2 Hz, -CH2-CH3), 7.09 (t, 1H, J = 8.0 Hz, Ar-H), 7.25 (t, 1H, J = 8.0 Hz, Ar-H), 7.47-
7.50 (m, 2H, Ar-H), 7.65-7.72 (m, 2H, Ar-H), 7.88-7.91 (m, 1H, Ar-H), 8.23-8.26 (m, 1H, Ar-
H),  8.71 (t, 1H, J = 2.0 Hz, Ar-H), 10.55 (s, 1H, -CONH), 11.81 (s, 1H, indole-NH) ppm. 
13C-NMR (DMSO-d6, 100 MHz): δ = 13.88, 62.60, 104.37, 112.43, 118.89, 120.03, 121.88, 
122.71, 123.15, 124.06, 124.59, 126.95, 130.30, 130.92, 136.96, 140.12, 157.18, 160.02, 
162.14, 176.45 ppm. MS (ESI): m/z (%) = 375.1 (M-H)-. IR (KBr): n = 3517, 3448, 3121, 
2981, 1735, 1653, 1573, 1540, 1478, 1445, 1412, 1314, 1240, 1212, 1108, 1029, 740, 680, 
633 cm-1. HRMS Calcd for C20H15N4O4 m/z: 375.1093 (M-H)-, found 375.1090. HPLC: tr = 
20.44 min (95.5% at 254 nm). 
 
4.3.15 Ethyl 5-(3-(5-fluoro-1H-indole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylate 
(15). Synthesized according to the general procedure for acidolytic cleavage of Boc protecting 
groups and the subsequent TBTU-mediated coupling. Yellow amorphous powder; m.p. 230-
232 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 1.38 (t, 3H, J = 7.2 Hz, -CH2-CH3), 4.47 (q, 2H, 
J = 7.2 Hz, -CH2-CH3), 7.13 (dt, 1H, J = 9.2 Hz, J = 2.4 Hz, Ar-H), 7.48-7.53 (m, 3H, Ar-H), 
7.69 (t, 1H, J = 8.0 Hz, Ar-H), 7.91 (dd, 1H, J = 8.0 Hz, J = 1.2 Hz, Ar-H), 8.24 (dd, 1H, J = 
8.0 Hz, J = 2.0 Hz, Ar-H), 8.71 (t, 1H, J = 2.0 Hz, Ar-H), 10.60 (s, 1H, -CONH), 11.93 (s, 
1H, indole-NH) ppm. MS (ESI): m/z (%) = 393.1 (M-H)-. IR (KBr): n = 3395, 3297, 1727, 
1658, 1560, 1538, 1489, 1449, 1402, 1380, 1357, 1290, 1226, 1144, 1110, 1027, 798, 757, 
741, 732 cm-1. HRMS Calcd for C20H14FN4O4 m/z: 393.0999 (M-H)-, found 393.1010. HPLC: 
tr = 21.22 min (97.3% at 254 nm). 
 
 
4.3.16 5-(3-(1H-pyrrole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylic acid (16). 
Synthesized according to the general procedure for alkaline hydrolysis described in [41]. 
Beige amorphous powder; m.p. 207-210 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 6.19-6.20 
(m, 1H, Ar-H), 7.01 (s, 1H, Ar-H), 7.13 (s, 1H, Ar-H), 7.61 (t, 1H, J = 8.0 Hz, Ar-H), 7.82 (d, 
1H, J = 8.0 Hz, Ar-H), 8.15 (dd, 1H, J = 8.0 Hz, J = 1.2 Hz, Ar-H), 8.63 (s, 1H, Ar-H), 10.08 
(s, 1H, -CONH), 11.74 (s, 1H, pyrrole-NH) ppm. 13C-NMR (DMSO-d6, 100 MHz): δ = 
109.08, 111.82, 118.58, 122.10, 123.11, 123.20, 124.23, 125.58, 130.10, 140.50, 158.57, 
159.33, 162.91, 176.31 ppm. MS (ESI): m/z (%) = 297.1 (M-H)-. IR (KBr): n = 3375, 3320, 
2924, 1712, 1624, 1597, 1574, 1547, 1531, 1509, 1484, 1420, 1337, 1224, 1166, 1127, 1082, 
1054, 999, 891, 762, 739, 679, 637 cm-1. HRMS Calcd for C14H9N4O4 m/z: 297.0624 (M-H)-, 
found 297.0630. HPLC: tr = 5.56 min (99.7% at 254 nm). 
 
4.3.17 5-(3-(4-Bromo-1H-pyrrole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylic acid 
(17). Synthesized according to the general procedure for alkaline hydrolysis described in [41]. 
Beige amorphous powder; m.p. 140-144 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 7.12-7.13 
(m, 1H, Ar-H), 7.19-7.20 (m, 1H, Ar-H), 7.48 (t, 1H, J = 8.0 Hz, Ar-H), 7.58 (dt, 1H, J = 7.6 
Hz, J = 1.2 Hz, Ar-H), 8.02 (dd, 1H, J = 8.0 Hz, J = 1.6 Hz, Ar-H), 8.26 (t, 1H, J =2.0 Hz, Ar-
H), 10.04 (s, 1H, -CONH), 12.09 (s, 1H, pyrrole-NH) ppm. 13C-NMR (DMSO-d6, 100 MHz): 
δ = 95.30, 113.01, 115.93, 119.68, 119.76, 122.71, 124.19, 126.28, 129.02, 139.41, 158.16, 
163.88, 164.96, 170.70 ppm. MS (ESI): m/z (%) = 375.0 (M-H)-. IR (KBr): n = 3260, 2960, 
2920, 1721, 1656, 1572, 1553, 1532, 1477, 1444, 1379, 1334, 1296, 1261, 1220, 1134, 1094, 
1016, 794, 742, 678 cm-1. HRMS Calcd for C14H8BrN4O4 m/z: 374.9729 (M-H)-, found 





acid (18). Synthesized according to the general procedure for alkaline hydrolysis described in 
[41].  Beige amorphous powder; m.p. 156-160 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 7.27 
(d, 1H, J = 2.8 Hz, Ar-H), 7.51 (t, 1H, J = 8.0 Hz, Ar-H), 7.59-7.61 (m, 1H, Ar-H), 8.02-8.04 
(m, 1H, Ar-H), 8.26 (s, 1H, Ar-H), 10.10 (s, 1H, -CONH), 12.97 (s, 1H, pyrrole-NH) ppm. 
13C-NMR (DMSO-d6, 100 MHz): δ = 98.27, 102.97, 106.36, 114.15, 119.67, 122.78, 124.44, 
127.54, 129.19, 131.41, 139.35, 148.64, 157.43, 174.77 ppm. MS (ESI): m/z (%) = 454.9 
(M+H)+. IR (KBr): n = 3206, 2964, 1725, 1636, 1573, 1555, 1539, 1477, 1420, 1386, 1337, 
1304, 1214, 742, 679 cm-1. HRMS Calcd for C14H9Br2N4O4 m/z: 454.8991 (M+H)+, found 
454.8998. HPLC: tr = 12.91 min (94.3% at 254 nm). 
 
4.3.19 5-(3-(1H-indole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylic acid (19).  
Synthesized according to the general procedure for alkaline hydrolysis described in [41]. 
Beige amorphous powder; m.p. 176-180 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 7.07 (t, 1H, 
J = 7.6 Hz, Ar-H), 7.23 (t, 1H, J = 7.6 Hz, Ar-H), 7.44-7.53 (m, 3H, Ar-H), 7.63-7.69 (m, 2H, 
Ar-H), 8.11 (dd, 1H, J = 8.8 Hz, J = 1.2 Hz, Ar-H), 8.35-8.45 (m, 1H, Ar-H), 10.45 (s, 1H, -
CONH), 11.78 (s, 1H, indole-NH) ppm. 13C-NMR (DMSO-d6, 100 MHz): δ = 104.21, 112.39, 
119.95, 120.76, 121.83, 122.98, 123.91, 124.23, 126.98, 128.95, 128.98, 131.10, 136.88, 
139.29, 148.92, 159.85, 167.17, 174.89 ppm. MS (ESI): m/z (%) = 349.1 (M+H)+. IR (KBr): 
n = 3283, 3197, 2963, 2920, 1651, 1611, 1590, 1538, 1476, 1440, 1414, 1228, 1193, 1144, 
1107, 741, 679 cm-1. HRMS Calcd for C18H13N4O4 m/z: 349.0937 (M+H)+, found 349.0938. 
HPLC: tr = 11.81 min (98.3% at 254 nm). 
 
4.3.20 5-(3-(5-Fluoro-1H-indole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylic acid 
(20). Synthesized according to the general procedure for alkaline hydrolysis described in [41]. 
 
 
Beige amorphous powder; m.p. 240-243 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 7.07-7.12 
(m, 1H, Ar-H), 7.41-7.47 (m, 4H, Ar-H), 7.66 (d, 1H, J = 7.6 Hz, Ar-H), 8.08 (d, 1H, J = 7.6 
Hz, Ar-H), 8.32 (s, 1H, Ar-H), 10.45 (s, 1H, -CONH), 11.89 (s, 1H, indole-NH) ppm. MS 
(ESI): m/z (%) = 321.1 (M-H-CO2)-. IR (KBr): n = 3397, 3299, 1662, 1540, 1477, 1446, 
1413, 1330, 1293, 1203, 1147, 1109, 795, 742, 676 cm-1. Anal. Calcd for C18H11FN4O4 × 1.7 
H2O (%): C, 54.47; H, 3.66; N, 14.11. Found: C, 54.52; H, 3.46; N, 13.93. HPLC: tr = 12.81 
min (93.3% at 254 nm). 
 
4.3.21 Ethyl 5-(3-(1H-indole-2-carboxamido)phenyl)-1,3,4-oxadiazole-2-carboxylate (22). 
Synthesized as described in [42]. Yellow amorphous powder; m.p. 225-227 °C. 1H-NMR 
(DMSO-d6, 400 MHz): δ = 1.39 (t, 3H, J = 7.2 Hz, -CH2-CH3), 4.48 (q, 2H, J = 7.2 Hz, -CH2-
CH3), 7.09 (t, 1H, J = 8.0 Hz, Ar-H), 7.25 (t, 1H, J = 8.0 Hz, Ar-H), 7.48-7.51 (m, 2H, Ar-H), 
7.65 (t, 1H, J = 8.0 Hz, Ar-H), 7.71 (d, 1H, J = 8.4 Hz, Ar-H), 7.82 (d, 1H, J = 8.8 Hz, Ar-H), 
8.21 (dd, 1H, J = 8.0 Hz, J = 2.0 Hz, Ar-H), 8.60-8.61 (m, 1H, Ar-H), 10.55 (s, 1H, -CONH), 
11.81 (s, 1H, indole-NH) ppm. 13C-NMR (DMSO-d6, 100 MHz): δ = 13.89, 62.91, 104.34, 
112.42, 117.94, 120.00, 121.87, 121.90, 122.96, 123.72, 124.02, 126.96, 130.20, 130.98, 
136.94, 140.10, 154.04, 156.51, 160.01, 165.29 ppm. MS (ESI): m/z (%) = 377.1 (M+H)+. IR 
(KBr): n = 3348, 3311, 3123, 3060, 2985, 1749, 1698, 1677, 1650, 1603, 1557, 1530, 1492, 
1475, 1455, 1404, 1383, 1365, 1352, 1316, 1289, 1229, 1203, 1167, 1103, 1082, 1028, 968, 
899, 872, 861, 838, 824, 800, 767, 746, 729, 684, 641, 613, 571, 555 cm-1. HRMS Calcd for 
C20H17N4O4 m/z: 377.1250 (M+H)+, found 377.1260. HPLC: tr =17.16 min (100% at 254 nm). 
 
4.3.22 N-(3-(1,3,4-oxadiazol-2-yl)phenyl)-1H-indole-2-carboxamide (23). Synthesized 
according to the general procedure for alkaline hydrolysis described in [41]. Grey amorphous 
powder; m.p. 238-240 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 7.09 (t, 1H, J = 8.0 Hz, Ar-
 
 
H), 7.24 (t, 1H, J = 8.0 Hz, Ar-H), 7.48-7.50 (m, 2H, Ar-H), 7.62 (t, 1H, J = 7.6 Hz, Ar-H), 
7.70 (d, 1H, J = 7.2 Hz, Ar-H), 7.76 (d, 1H, J = 8.0 Hz, Ar-H), 8.12 (s, 1H, Ar-H), 8.59 (s, 
1H, Ar-H), 9.38 (s, 1H, Ar-H), 10.51 (s, 1H, -CONH), 11.80 (s, 1H, indole-NH) ppm. MS 
(ESI): m/z (%) = 303.1 (M-H)-. IR (KBr): n = 3296, 2331, 2016, 1656, 1569, 1538, 1474, 
1445, 1417, 1329, 1311, 1242, 1191, 1146, 1117, 1086, 961, 896, 872, 793, 731, 681, 638, 
610, 602, 577, 565, 555 cm-1. HRMS Calcd for C17H11N4O2 m/z: 303.0882 (M-H)-, found 
303.0877. HPLC: tr =11.44 min (96.4% at 254 nm). 
 
4.3.23 5-(3-(1H-indole-2-carboxamido)phenyl)-1,3,4-oxadiazole-2-carboxamide (24). 
Synthesized according to the general procedure for aminolysis described in [40]. White 
amorphous powder; m.p. 264-268 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 7.09 (t, 1H, J = 
7.6 Hz, Ar-H), 7.25 (t, 1H, J = 8.0 Hz, Ar-H), 7.48-7.50 (m, 2H, Ar-H), 7.71 (d, 1H, J = 8.0 
Hz, Ar-H), 7.81 (d, 1H, J = 8.0 Hz, Ar-H), 8.17 (dd, 1H, J = 8.0 Hz, J = 2.0 Hz, Ar-H), 8.28 
(s, 1H, CONH2), 8.61 (t, 1H, J = 1.6 Hz, Ar-H), 8.71 (s, 1H, CONH2), 10.54 (s, 1H, -CONH), 
11.81 (s, 1H, indole-NH) ppm. 13C-NMR (DMSO-d6, 100 MHz): δ = 104.30, 112.42, 118.00, 
120.00, 121.87, 123.24, 124.01, 126.97, 130.10, 131.00, 136.93, 139.99, 153.41, 154.54, 
158.62, 159.98, 165.00, 167.33 ppm. MS (ESI): m/z (%) = 346.1 (M-H)-. IR (KBr): n = 3307, 
3193, 2926, 2359, 2162, 1987, 1957, 1702, 1651, 1597, 1565, 1531, 1419, 1341, 1312, 1279, 
1238, 1190, 1145, 1105, 1079, 999, 885, 852, 793, 740, 707, 677, 623, 616, 601, 591, 574, 
561, 553 cm-1. HRMS Calcd for C18H12N5O3 m/z: 346.0940 (M-H)-, found 346.0949. HPLC: 
tr = 9.98 min (100.0% at 254 nm). 
 
4.3.24 5-(3-(1H-indole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxamide (25). 
Synthesized according to the general procedure for aminolysis described in [40]. White 
amorphous powder; m.p. 288-290 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 7.10 (t, 1H, J = 
 
 
7.2 Hz, Ar-H), 7.26 (t, 1H, J = 7.2 Hz, Ar-H), 7.49-7.51 (m, 2H, Ar-H), 7.66-7.73 (m, 2H, Ar-
H), 7.90 (dd, 1H, J = 7.6 Hz, J = 1.2 Hz, Ar-H), 8.17-8.20 (m, 2H, Ar-H, CONH2), 8.44 (s, 
1H, CONH2), 8.71 (t, 1H, J = 2.0 Hz, Ar-H), 10.57 (s, 1H, -CO-NH-), 11.81 (s, 1H, indole-
NH) ppm. 13C-NMR (DMSO-d6, 100 MHz): δ = 104.39, 112.43, 118.90, 120.03, 121.88, 
122.83, 124.06, 124.57, 126.95, 130.23, 130.93, 136.95, 140.03, 147.64, 157.77, 160.02, 
164.39, 175.86 ppm. MS (ESI): m/z (%) = 346.1 (M-H)-. IR (KBr): n = 3471, 3355, 3301, 
3117, 1690, 1655, 1619, 1598, 1566, 1540, 1491, 1445, 1399, 1317, 1272, 1229, 1201, 1150, 
735, 680, 642 cm-1. HRMS Calcd for C18H12N5O4 m/z: 346.0940 (M-H)-, found 346.0945. 
HPLC: tr = 11.23 min (100.0% at 254 nm). 
 
4.3.25 5-(3-(1H-indole-2-carboxamido)phenyl)-N-hydroxy-1,2,4-oxadiazole-3-carboxamide 
(26). Synthesized according to the procedure described in [40]. White amorphous powder; 
m.p. 187-190 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 7.10 (t, 1H, J = 7.6 Hz, Ar-H), 7.26 (t, 
1H, J = 8.0 Hz, Ar-H), 7.49-7.52 (m, 2H, Ar-H), 7.67 (d, 1H, J = 7.6 Hz, Ar-H), 7.71 (d, 1H, 
J = 8.4 Hz, Ar-H), 7.89 (d, 1H, J = 8.0 Hz, Ar-H), 8.20 (dd, 1H, J = 9.6 Hz, J = 1.2 Hz, Ar-
H), 8.73 (s, 1H, Ar-H), 10.23 (s, 1H, -NH-OH), 10.63 (s, 1H, -CO-NH-), 11.85 (s, 1H, indole-
NH), 11.96 (s, 1H, -NH-OH) ppm. 13C-NMR (DMSO-d6, 100 MHz): δ = 104.52, 112.43, 
118.93, 120.02, 121.87, 122.85, 123.26, 124.05, 124.66, 126.94, 130.22, 130.95, 136.95, 
140.07, 153.58, 160.00, 163.27, 175.82 ppm. MS (ESI): m/z (%) = 362.1 (M-H)-. IR (KBr): n 
= 3396, 3348, 3185, 1640, 1618, 1568, 1533, 1475, 1440, 1413, 1364, 1326, 1311, 1244, 746 
cm-1. HRMS Calcd for C18H12N5O4 m/z: 362.0889 (M-H)-, found 362.0883. HPLC: tr = 9.50 
min (82.5% at 254 nm). 
 
4.3.26 Ethyl 5-(4-(1H-indole-2-carboxamido)benzyl)-1,2,4-oxadiazole-3-carboxylate (28). 
Synthesized according to the general procedure for acidolytic cleavage of Boc protecting 
 
 
groups and the subsequent TBTU-mediated coupling. Beige solid; m.p. 189-193 °C. 1H-NMR 
(DMSO-d6, 400 MHz): δ = 1.31 (t, 3H, J = 7.2 Hz, -CH2-CH3), 4.39 (q, 2H, J = 7.2 Hz, -CH2-
CH3), 4.43 (s, 2H, Ar-CH2), 7.07 (t, 1H, J = 8.0 Hz, Ar-H), 7.22 (dt, 1H, J = 8.0 Hz, J = 1.2 
Hz, Ar-H), 7.36 (d, 2H, J = 8.8 Hz, Ar-H), 7.43-7.47 (m, 2H, Ar-H), 7.68 (d, 1H, J = 8.0 Hz, 
Ar-H), 7.81 (d, 2H, J = 8.4 Hz, Ar-H), 10.29 (s, 1H, -CONH), 11.78 (s, 1H, NH) ppm. 13C-
NMR (DMSO-d6, 100 MHz): δ = 13.83, 31.39, 62.47, 103.96, 112.36, 119.90, 120.38, 
121.73, 123.78, 126.97, 128.48, 129.51, 131.35, 136.80, 138.27, 157.17, 159.70, 161.61, 
180.43 ppm. MS (ESI): m/z (%) = 389.1 (M-H)-. IR (KBr): n = 3275, 2932, 1692, 1600, 
1529, 1374, 1341, 1308, 1233, 1198, 1147, 1090, 968, 780, 740 cm-1. HRMS Calcd for 




carboxylate (29). Synthesized according to the general procedure for acidolytic cleavage of 
Boc protecting groups and the subsequent TBTU-mediated coupling. Ochre solid; m.p. 185-
187 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 1.32 (t, 3H, J = 7.2 Hz, -CH2-CH3), 4.37-4.42 
(m, 4H, -CH2-CH3 and Ar-CH2), 7.25 (s, 1H, Ar-H), 7.33 (d, 1H, J = 8.8 Hz, Ar-H), 7.69-7.73 
(m, 2H, Ar-H), 9.96 (s, 1H, -CONH), 12.96 (s, 1H, NH) ppm. 13C-NMR (DMSO-d6, 100 
MHz): δ = 13.82, 31.36, 62.47, 98.15, 105.87, 113.99, 120.19, 127.82, 129.48, 138.13, 
142.42, 157.16, 157.26, 161.59, 180.42 ppm. MS (ESI): m/z (%) = 494.9 (M-H)-. IR (KBr): n 
= 3399, 3323, 1651, 1596, 1519, 1448, 1408, 1341, 1317, 1222, 1189, 1142, 799, 742, 639 
cm-1. HRMS Calcd for C17H13Br2N4O4 m/z: 494.9309 (M-H)-, found 494.9312. HPLC: tr = 




4.3.28 5-(4-(1H-indole-2-carboxamido)benzyl)-1,2,4-oxadiazole-3-carboxylic acid (30). 
Synthesized according to the general procedure for alkaline hydrolysis described in [41]. 
Beige solid; m.p. 221-223 °C. 1H-NMR (DMSO-d6, 400 MHz): δ = 3.67 (s, 2H, Ar-CH2), 
7.05-7.09 (m, 2H, Ar-H), 7.21-7.27 (m, 3H, Ar-H), 7.42-7.48 (m, 2H, Ar-H), 7.63-7.77 (m, 
2H, Ar-H), 10.24 (s, 1H, -CONH), 11.75 (s, 1H, NH), 12.89 (s, 1H, COOH) ppm. 13C-NMR 
(DMSO-d6, 100 MHz): δ = 30.67, 103.85, 107.26, 112.45, 119.92, 120.16, 121.91, 124.24, 
126.99, 128.36, 129.72, 131.40, 136.79, 137.90, 159.67, 162.79, 172.08 ppm. MS (ESI): m/z 
(%) = 363.1 (M+H)+. IR (KBr): n = 3401, 1650, 1596, 1533, 1448, 1408, 1341, 1317, 1223, 
1189, 1146, 799, 742, 640 cm-1. HRMS Calcd for C19H15N4O4 m/z: 363.1093 (M+H)+, found 
363.1095. HPLC: tr = 11.40 min (93.9% at 254 nm). 
 
4.3.29 5-(4-(4,5-Dibromo-1H-pyrrole-2-carboxamido)benzyl)-1,2,4-oxadiazole-3-carboxylic 
acid (31). Synthesized according to the general procedure for alkaline hydrolysis described in 
[41]. Beige solid; m.p. 218-220 °C. 1H-NMR (MeOD, 400 MHz): δ = 3.67 (s, 2H, Ar-CH2), 
7.07 (s, 1H, Ar-H), 7.25 (d, 2H, J = 8.0 Hz, Ar-H), 7.64 (d, 2H, J = 8.0 Hz, Ar-H) ppm. 13C-
NMR (MeOD, 100 MHz): δ = 42.17, 100.23, 107.00, 115.10, 118.64, 122.06, 128.98, 130.20, 
130.82, 139.03, 159.78, 164.63, 173.69 ppm. MS (ESI): m/z (%) = 468.9 (M+H)+. IR (KBr): 
n = 3397, 2917, 2849, 1687, 1651, 1516, 1449, 1369, 1319, 1244, 1174, 1145, 1070, 1011, 
976, 927, 853, 800, 749, 608 cm-1. HRMS Calcd for C15H11Br2N4O4 m/z: 468.9147 (M+H)+, 
found 468.9140. HPLC: tr = 12.49 min (94.8% at 254 nm). 
 
4.3.30 Ethyl 5-((4-aminophenyl)amino)-1,2,4-oxadiazole-3-carboxylate (33). Synthesized 
from 46 according to the procedure for nucelophilic displacement described in [44]. Brown 
solidified oil; m.p. /. 1H-NMR (DMSO-d6, 400 MHz): δ = 1.29 (t, 3H, J = 7.2 Hz, -CH2-CH3), 
4.35 (q, 2H, J = 7.2 Hz, -CH2-CH3) 5.05 (s, 2H, NH2), 6.58 (d, 2H, J = 8.8 Hz, Ar-H), 7.15 (d, 
 
 
2H, J = 8.4 Hz, Ar-H), 10.72 (s, 1H, NH) ppm. 13C-NMR (DMSO-d6, 100 MHz): δ = 14.37, 
62.60, 120.95, 128.53, 133.19, 138.93, 139.44, 158.41, 169.79 ppm. MS (ESI): m/z (%) = 
249.9 (M+H)+. IR (KBr): n = 2983, 1736, 1628, 1592, 1512, 1412, 1385, 1202, 831, 733, 626 
cm-1. HRMS Calcd for C11H12N4O3 m/z: 249.0988 (M+H)+, found 249.0988.  
 
4.3.31 5-((4-(4,5-Dibromo-1H-pyrrole-2-carboxamido)phenyl)amino)-1,2,4-oxadiazole-3-
carboxylic acid (34). To a stirred solution of 4,5-dibromo-pyrrole-2-carboxylic acid (1.0 eq) 
in dry dichloromethane (10 mL), diisopropylethylamine (3.0 eq) and TBTU (1.1 eq) were 
added. After stirring for 45 minutes the amine 33 was added at 0 °C, and the mixture allowed 
to warm to room temperature; stirring then continued for 48 h. On completion, the reaction 
mixture was diluted with dichloromethane (30 mL) then washed with 1M HCl (2 × 20 mL), 
water (20 mL), saturated NaHCO3 solution (2 × 20 mL), water (20 mL) and dried over 
anhydrous Na2SO4. The solvent was concentrated in vacuo and the residue of crude ester 
immediately used in the next step. The crude ester (1.0 eq) was dissolved in THF, then 1M 
NaOH (1.1 eq) was added and the reaction mixture stirred at room temperature for 2 h. THF 
was evaporated under vacuum and the resulting aqueous solution neutralized with 1M HCl 
until the product 34 precipitated. It was then dried overnight. Brown solid; m.p. 200-203 °C. 
1H-NMR (DMSO-d6, 400 MHz): δ = 7.19 (s, 1H, Ar-H), 7.41 (d, 2H, J = 8.8 Hz, Ar-H), 7.55 
(d, 2H, J = 8.8 Hz, Ar-H), 8.99 (s, 1H, Ar-NH), 9.77 (s, 1H, CONH), 12.87 (s, 1H, NH) ppm. 
13C-NMR (DMSO-d6, 100 MHz): δ = 99.03, 106.17, 113.49, 117.18, 120.97, 124.64, 125.26, 
127.59, 139.83, 160.97, 160.98, 185.55 ppm. MS (ESI): m/z (%) = 423.9 (M-H-CO2)-. IR 
(KBr): n = 3394, 3322, 1651, 1597, 1515, 1448, 1408, 1372, 1342, 1318, 1223, 1189, 1143, 
800, 740, 630 cm-1. HRMS Calcd for C13H8Br2N5O2 m/z: 423.9045 (M+H)+, found 423.9034. 




oxadiazole-3-carboxylic acid (35). To a stirred solution of 3,4-dichloro-5-methyl-pyrrole-2-
carboxylic acid (1.0 eq) in dry dichloromethane (10 mL), diisopropylethylamine (3.0 eq) and 
TBTU (1.1 eq) were added. After stirring for 45 minutes the amine 33 was added at 0 °C, and 
the mixture allowed to warm to room temperature; stirring then continued for 48 h. On 
completion, the reaction mixture was diluted with dichloromethane (30 mL) then washed with 
1M HCl (2 × 20 mL), water (20 mL), saturated NaHCO3 solution (2 × 20 mL), water (20 mL) 
and dried over anhydrous Na2SO4. The solvent was concentrated in vacuo and the residue of 
crude ester immediately used in the next step. The crude ester (1.0 eq) was dissolved in THF, 
then 1M NaOH (1.1 eq) was added and the reaction mixture stirred at room temperature for 2 
h. THF was evaporated under vacuum and the resulting aqueous solution neutralized with 1M 
HCl until the product 35 precipitated. It was then dried overnight. Brown solid; m.p. 176-180 
°C. 1H-NMR (DMSO-d6, 400 MHz): δ = 2.22 (s, 3H, Ar-CH3), 7.40 (d, 2H, J = 8.8 Hz, Ar-
H), 7.57 (d, 2H, J = 8.8 Hz, Ar-H), 9.35 (s, 1H, Ar-NH), 9.36 (s, 1H, CONH), 12.14 (s, 1H, 
NH) ppm. 13C-NMR (DMSO-d6, 100 MHz): δ = 10.75, 108.28, 110.89, 119.63, 119.67, 
120.48, 127.81, 133.80, 134.31, 151.96, 157.00, 180.65 ppm. MS (ESI): m/z (%) = 350.0 (M-
H-CO2)-. IR (KBr): n = 3394, 3321, 1651, 1598, 1515, 1449, 1409, 1373, 1317, 1249, 1190, 
1130, 1045, 960, 800, 738, 627 cm-1. HRMS Calcd for C14H10Cl2N5O2 m/z: 350.0212 
(M+H)+, found 350.0217. HPLC: tr = 12.44 min (97.2% at 254 nm). 
 
4.4 In vitro Inhibitory Activity Screening and Determination of IC50 Values on E. coli 
and S. aureus Gyrase. The assay for determining IC50 values (Inspiralis) was performed on 
black streptavidin-coated 96-well microtiter plates (Thermo Scientific Pierce). The plate was 
first rehydrated with the wash buffer supplied (20 mM Tris-HCl (pH 7.6), 137 mM NaCl, 
0.01% (w/v) BSA, 0.05% (v/v) Tween 20). Biotinylated oligonucelotide was immobilized 
 
 
onto the wells. The excess of oligonucleotide was then washed off and the enzyme assay 
carried out in the wells. The final reaction volume of 30 μL in buffer (35 mM Tris  HCl pH 
7.5; 24 mM KCl; 4 mM MgCl2; 2 mM DTT; 1.8 mM spermidine; 1 mM ATP; 6.5 % (w/v) 
glycerol; 0.1 mg/mL albumin) contained 1.5 U of DNA gyrase from E. coli or S. aureus, 0.75 
μg of relaxed pNO1 plasmid, and 3 μL of inhibitors solution in 10% DMSO and 0.008% 
Tween® 20. Reactions were incubated for 30 min at 37 °C and, after addition of the TF buffer 
(50 mM NaOAc pH 5.0, 50 mM NaCl and 50 mM MgCl2), which terminated the enzymatic 
reaction, for another 30 min at room temperature to allow triplex formation 
(biotin−oligonucleotide−plasmid). The unbound plasmid was then washed off using TF 
buffer, and a solution of SybrGOLD stain in T10 buffer (10 mM Tris × HCl pH 8.0 and 1 mM 
EDTA) was added. After mixing, the fluorescence (excitation, 485 nm; emission, 535 nm) 
was read using a BioTek's Synergy H4 microplate reader. Preliminary screening was 
performed at inhibitor concentrations of 100 μM and 10 μM. For the most potent compounds 
IC50 was determined with 7 concentrations of the inhibitors. IC50 values were calculated using 
GraphPad Prism software and represent the concentration of inhibitor where the residual 
activity of the enzyme is 50% in three independent measurements; the final result is given as 
their average value. Novobiocin (IC50 = 0.17 μM (lit. 0.08 μM [45]) for E. coli DNA gyrase 
and IC50 = 0.041 μM (lit. 0.01 μM [45]) for S. aureus DNA gyrase) was used as a positive 
control. 
4.5 In vitro Inhibitory Activity Screening and Determination of IC50 Values on E. coli 
and S. aureus topoisomerase IV. The assay for the determination of IC50 values (Inspiralis) 
was performed on the black streptavidin-coated 96-well microtiter plates (Thermo Scientific 
Pierce). The plate was first rehydrated with the supplied wash buffer (20 mM Tris-HCl (pH 
7.6), 137 mM NaCl, 0.01% (w/v) BSA, 0.05% (v/v) Tween® 20) and biotinylated 
oligonucelotide was immobilized onto the wells. The excess of oligonucleotide was then 
 
 
washed off, and the enzyme assay carried out in the wells. The final reaction volume of 30 μL 
in buffer (40 mM HEPES KOH (pH 7.6), 100 mM potassium glutamate, 10 mM magnesium 
acetate, 10 mM DTT, 1 mM ATP, 0.05 mg/mL albumin) contained 1.5 U of topoisomerase IV 
from E. coli or S. aureus, 0.75 μg of supercoiled pNO1 plasmid, and 3 μL of inhibitors 
solution in 10% DMSO and 0.008% Tween 20. Reactions were incubated for 30 min at 37 °C, 
and after addition of the TF buffer (50 mM NaOAc pH 5.0, 50 mM NaCl and 50 mM MgCl2), 
which terminated the enzymatic reaction, for another 30 min at room temperature to allow 
triplex formation (biotin−oligonucleotide−plasmid). The unbound plasmid was then washed 
off using TF buffer and the solution of SybrGOLD stain in T10 buffer (10 mM Tris-HCl pH 
8.0 and 1 mM EDTA) was added. After mixing, fluorescence (excitation, 485 nm; emission, 
535 nm) was read using a BioTek's Synergy H4 microplate reader. Preliminary screening was 
performed at inhibitor concentrations of 100 μM and 10 μM. For most potent compounds IC50 
was determined with 7 concentrations of the inhibitors. IC50 values were calculated using 
GraphPad Prism software and represent the concentration of inhibitor where the residual 
activity of the enzyme is 50% in three independent measurements; the final result is given as 
their average value. Novobiocin (IC50 = 11 μM (lit. 10 μM [45]) for E. coli topoisomerase IV 
and IC50 = 27 μM (lit. 20 μM [45])   for S. aureus topoisomerase IV) was used as a positive 
control.    
4.6 Determination of Antibacterial Activity. Antimicrobial assays were performed by the 
broth microdilution method following the guidelines of the Clinical and Laboratory Standards 
Institute (CLSI; Methods for dilution antimicrobial susceptibility tests for bacteria that grow 
aerobically, Approved standards – Ninth Edition; M07-A9, Vol.32 No.2). The following 
CLSI recommended quality control strains for susceptibility testing were used in the 
antibacterial assays: Enterococcus faecalis (Gram positive, ATCC 29212), Staphylococcus 
aureus (Gram positive, ATCC 25923), Escherichia coli (Gram negative, ATCC 25922) and 
 
 
Pseudomonas aeruginosa (Gram negative, ATCC 27853). Primary screening of compounds 
against the ATCC strains was initially carried out at a final concentration of 50 µM (n = 3). 
Compound 35 that showed >80% inhibition against E. faecalis in the primary screen was 
tested further at 10 different concentrations to confirm its activity and to determine the MIC90 
concentration (lowest concentration inhibitingthe growth by >90%). Ciprofloxacin (ICN 
Biomedicals Inc., USA) was used as positive control on every assay plate at MIC90 
concentration. 
  
4.7 Molecular Modeling. 
Ligand and Protein Preparation. Three-dimensional models of designed compounds were 
built in ChemBio3D Ultra 13.0 [46] Their geometries were optimized using MMFF94 [47] 
force field and partial atomic charges were added. Energy was minimized until the gradient 
value was smaller than 0.001 kcal/(mol Å). The optimized structure was further refined with 
GAMESS interface in ChemBio3D Ultra 13.0 using the semiempirical PM3 method, QA 
optimization algorithm and Gasteiger Hückel charges for all atoms for 100 steps [47]. 
Molecular docking calculations were performed using FlexX [48,49], as available in LeadIT 
[37], running on four octal core AMD Opteron CPU processors, 16 GB RAM, two 750 GB 
hard drives, running 64-bit Scientific Linux 6.0. Receptor was prepared in a LeadIT graphical 
user interface using the Receptor wizard. Amino acid residues within a radius of 7 Å around 
the ligand from the X-ray structure (PDB entry: 4DUH [39]) were defined as the binding site. 
Hydrogen atoms were added to the binding site residues and correct tautomers and 
protonation states were assigned. Water molecules, except HOH614, and the ligand were 
deleted from the crystal structure. 
Ligand Docking. The FlexX molecular docking program, as available in LeadIT [37], was 
used for ligand docking. A hybrid algorithm (enthalpy and entropy driven ligand binding) was 
 
 
used to place the ‘base fragment’. The maximum number of solutions per iteration and the 
maximum number of solutions per fragmentation parameter values were increased to 1000, 
while other parameters were set at their default values.  
Proposed binding modes and scoring function scores of the top five highest scored docking 
poses per ligand were evaluated and the highest ranked binding pose was used for graphical 
representation in PyMOL 3.1 [38]. 
 
Supporting Information. 1H and 13C NMR spectra of representative compounds. This 
material is available free of charge via the Internet.  
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RESEARCH HIGHLIGHTS 
• Structurally novel inhibitors of DNA gyrase were revealed by computer aided design 
• Oxadiazoles identified as balanced inhibitors of DNA gyrase and topoisomerase IV  
• Structural requirements for DNA gyrase and topo IV inhibition were identified 
 
GRAPHICAL ABSTRACT 

























a b  
Figure 4. The binding mode of inhibitors a) 19 (in green sticks) and b) 34 (in yellow sticks) in the ATP-
binding site of E. coli DNA gyrase B (PDB code: 4DUH) as predicted by docking with LeadIT [37]. The ligand 
and neighboring protein side chains are colored according to the chemical atom type (C19 in green, C34 in yellow, 
CGyrB in gray, N in blue, O in red, and Br in brown). Hydrogen bonds are indicated by black dotted lines. Figure 
was prepared by PyMOL [38]. 
 
